Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

PFIZER INC
Mes dernières consult.
Most popular
Report
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Pfizer Inc. : Pfizer Will Remove Claims on Breast and Colon Health From Centrum Label -Reuters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/05/2012 | 11:26pm CET

Pfizer Inc. (>> Pfizer Inc.) said it will remove claims that its Centrum multivitamin supplements promote breast and colon health from labels over the next six months, following a complaint by a watchdog group, Reuters reported Thursday.

The company will also revise websites and advertising for Centrum, the report said.

The report said the Center for Science in the Public Interest sent a letter to Pfizer Chief Executive Ian Read in April outlining its complaints and threatening a lawsuit if the claims weren't removed.

In a statement, Pfizer said it "disagrees with CSPI's concerns, but has agreed to make these changes in order to fully resolve the issues raised by the organization," Reuters reported.

Full story at http://www.reuters.com/article/2012/07/05/pfizer-centrum-idUSL2E8I5BR820120705

Write to [email protected]

Stocks mentioned in the article : Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER INC
12/16 PFIZER : US regulators approve Pfizers Remicade biosimilar
12/16 PFIZER : weighs `strategic options` for newly FDA-approved Remicade biosim, its ..
12/15 DOW MOVERS : Ibm, pfe
12/15 PFIZER INC. : Announces Expiration and Results of its Private Exchange Offer for..
12/15 PFIZER : Kirsten Lund-Jurgensen Named to Executive Committee of Manufacturers As..
12/15 PFIZER : U.S. Food And Drug Administration Extends Action Date For XELJANZ (Tofa..
12/15 Germany's Merck in fresh bid to enter U.S. MS pill market
12/15 PFIZER : `No plans to launch second approved Remicade biosimilar in US`
12/15 PFIZER : Fda approves new pfizer biosimilar
12/15 PFIZER : Preliminary Data from Servier and Pfizer's UCART19 Product Candidate Sh..
More news
News from SeekingAlpha
2015 Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2015 Update
2015 Antibiotics Stocks To Benefit From 21st Century Cures Act
2015 ISIS PHARMA STOCK DROPS ON GOOD NEWS : Re-Evaluating The Bull Case
2015 DOW DOGS : 14.63% More Returns From 5 Lowest Priced As Of August 6 Per indexArb
2015 Pfizer's GL-2045 an Orphan Drug for CIDP
Financials ($)
Sales 2017 52 550 M
EBIT 2017 19 881 M
Net income 2017 10 958 M
Debt 2017 23 944 M
Yield 2017 3,43%
P/E ratio 2017 19,95
P/E ratio 2018 17,20
EV / Sales 2017 4,68x
EV / Sales 2018 4,54x
Capitalization 222 B
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 38,2 $
Spread / Average Target 2,8%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Mikael Dolsten President-Worldwide Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC221 738
JOHNSON & JOHNSON22.95%382 722
PFIZER12.25%221 738
NOVARTIS13.09%221 731
ROCHE HOLDING LTD.3.91%212 270
MERCK AND COMPANY-4.86%153 386